Cruz A B, Metter G, Armstrong D M, Aust J B, Fletcher W S, Wilson W L, Richardson J D
Cancer. 1976 Sep;38(3):1069-76. doi: 10.1002/1097-0142(197609)38:3<1069::aid-cncr2820380305>3.0.co;2-1.
CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea, NSC-79037) was used to treat advanced malignancies in 329 evaluable patients. The treatment dosage was 130 mg/m2 for patients with adequate bone marrow reserve and 100 mg/m2 for those with compromised bone marrow. Oral treatment was repeated at 6-week intervals unless hematologic toxicity intervened. There were four complete responses: two in ovarian cancer, one with small cell carcinoma of the lung, and one with melanoma. Tumor response greater than 50% reduction in tumor size occurred in 39 patients (11.9%) while stable disease (no change or decrease or increase of less than 50% in tumor size) was noted in 152 patients (46.2%). Tumor progression occurred in 130 cases. Melanomas and ovarian and lung cancers had the highest response rates. Bone marrow depression was the major side effect of treatment; there was a significant positive correlation between the severity of leukopenia and thrombocytopenia and tumor response to treatment.
环己亚硝脲（1-[2-氯乙基]-3-环己基-1-亚硝基脲，NSC-79037）用于治疗329例可评估的晚期恶性肿瘤患者。对于骨髓储备充足的患者，治疗剂量为130mg/m²；对于骨髓功能受损的患者，治疗剂量为100mg/m²。除非出现血液学毒性，口服治疗每6周重复一次。有4例完全缓解：2例为卵巢癌，1例为肺小细胞癌，1例为黑色素瘤。39例患者（11.9%）出现肿瘤反应，肿瘤大小缩小超过50%，152例患者（46.2%）病情稳定（肿瘤大小无变化或缩小或增大小于50%）。130例出现肿瘤进展。黑色素瘤、卵巢癌和肺癌的缓解率最高。骨髓抑制是治疗的主要副作用；白细胞减少和血小板减少的严重程度与肿瘤对治疗的反应之间存在显著正相关。
